Cost-Effectiveness Analysis of Three Diagnostic Strategies for the Detection of EGFR Mutation in Advanced Non-Small Cell Lung Cancer
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: In non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutation testing of tumor tissue should be conducted at diagnosis. Alternatively, circulating tumor DNA can be used to detect EGFR mutation. We compared the cost and clinical effect of three strategies according to the application of the EGFR test. Methods: Decision models were developed to compare the cost-effectiveness of tissue-only, tissue-first, and plasma-first diagnostic strategies as first- and second-line treatments for NSCLC from the perspective of the Korean national healthcare payer. Progression-free survival (PFS), overall survival (OS), and direct medical costs were assessed. A one-way sensitivity analysis was performed. Results: The plasma-first strategy correctly identified numerous patients in the first- and second-line treatments. This strategy also decreased the cost of biopsy procedures and complications. Compared with that when using the other two strategies, the plasma-first strategy increased PFS by 0.5 months. The plasma-first strategy increased OS by 0.9 and 1 month compared with that when using the tissue-only and tissue-first strategies, respectively. The plasma-first strategy was the least expensive first-line treatment but the most expensive second-line treatment. First-generation tyrosine kinase inhibitor and the detection rate of the T790M mutation in tissues were the most cost-influential factors. Conclusions: The plasma-first strategy improved PFS and OS, allowing for a more accurate identification of candidates for targeted therapy for NSCLC and decreased biopsy- and complication-related costs.
Abstract
Background: In non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutation testing of tumor tissue should be conducted at diagnosis. Alternatively, circulating tumor DNA can be used to detect EGFR mutation. We compared the cost and clinical effect of three strategies according to the application of the EGFR test. Methods: Decision models were developed to compare the cost-effectiveness of tissue-only, tissue-first, and plasma-first diagnostic strategies as first- and second-line treatments for NSCLC from the perspective of the Korean national healthcare payer. Progression-free survival (PFS), overall survival (OS), and direct medical costs were assessed. A one-way sensitivity analysis was performed. Results: The plasma-first strategy correctly identified numerous patients in the first- and second-line treatments. This strategy also decreased the cost of biopsy procedures and complications. Compared with that when using the other two strategies, the plasma-first strategy increased PFS by 0.5 months. The plasma-first strategy increased OS by 0.9 and 1 month compared with that when using the tissue-only and tissue-first strategies, respectively. The plasma-first strategy was the least expensive first-line treatment but the most expensive second-line treatment. First-generation tyrosine kinase inhibitor and the detection rate of the T790M mutation in tissues were the most cost-influential factors. Conclusions: The plasma-first strategy improved PFS and OS, allowing for a more accurate identification of candidates for targeted therapy for NSCLC and decreased biopsy- and complication-related costs.
참고문헌 (33)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~86 (2015)
- Annual report of cancer statistics in Korea in 2017, "Korea Central Cancer Registry, National Cancer Center", Ministry of Health and Welfare, ~ (2017)
- Lim C, "Patients with advanced non-small cell lung cancer : are research biopsies a barrier to participation in clinical trials?", J Thorac Oncol, 11, pp.79~84 (2016)
- Eberhard DA, "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib", J Clin Oncol, 23, pp.5900~5909 (2005)
- Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)
- Cross DA, "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer", Cancer Discov, 4, pp.1046~1061 (2014)
- Goldman JW, "Are liquid biopsies a surrogate for tissue EGFR testing?", Ann Oncol, 29(Suppl 1), pp.i38~i46 (2018)
- Goto K, "Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin", paclitaxel in non-small cell lung cancer, 2012, pp.7, 115~121
- Diaz LA Jr, "Liquid biopsies : genotyping circulating tumor DNA", J Clin Oncol, 32, pp.579~586 (2014)
- Karlovich C, "Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib(CO-1686)", Clin Cancer Res, 22, pp.2386~2395 (2016)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Fukuoka M, "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS), 2011, pp.29, 2866~2874
- Wu Y-L, "Overall survival(OS)from the AURA3 phase III study : osimertinib vs platinum-pemetrexed(plt-pem)in patients(pts)with EGFR T790M advanced non-small cell lung cancer(NSCLC)and progression on a prior EGFR-tyrosine kinase inhibitor(TKI)", Ann Oncol, 30, pp.IX158~ (2019)
- Mok TS, "Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer", N Engl J Med, 376, pp.629~640 (2017)
- Oxnard GR, "Association between plasma genotyping and outcomes of treatment with osimertinib(AZD9291)in advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.3375~3382 (2016)
- Sands J, "Urine circulating-tumor DNA(ctDNA)detection of acquired EGFR T790M mutation in non-small-cell lung cancer : an outcomes and total cost-of-care analysis", Lung Cancer, 110, pp.19~25 (2017)
- Jenkins S, "Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer", J Thorac Oncol, 12, pp.1061~1070 (2017)
- Thress KS, "EGFR mutation detection in ctDNA from NSCLC patient plasma : a cross-platform comparison of leading technologies to support the clinical development of AZD9291", Lung Cancer, 90, pp.509~515 (2015)
- Goldman JW, "EGFR genotyping of matched urine, plasma, and tumor tissue in patients with non-small-cell lung cancer treated with rociletinib, an EGFR tyrosine kinase inhibitor", JCO Precis Oncol, 2, pp.1~13 (2018)
- Heerink WJ, "Complication rates of CT-guided transthoracic lung biopsy : meta-analysis", Eur Radiol, 27, pp.138~148 (2017)
- Covey AM, "Factors associated with pneumothorax and pneumothorax requiring treatment after percutaneous lung biopsy in 443 consecutive patients", J Vasc Interv Radiol, 15, pp.479~483 (2004)
- Wiener RS, "Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule : an analysis of discharge records", Ann Intern Med, 155, pp.137~144 (2011)
- Ettinger DS, "NCCN clinical practice guidelines in oncology. Non-small cell lung cancer, Version 5", ~ (2021)
- Rolfo C, "Liquid biopsy for advanced NSCLC : a consensus statement from the International Association for the Study of Lung Cancer", J Thorac Oncol, 16, pp.1647~1662 (2021)
- Gancitano G, "Cost-consequence analysis of three different diagnostic strategies in the first-and second-line treatment of locally advanced or metastatic non-small-cell lung cancer", Farmeconomia, Health Economics and Therapeutic Pathways (2018)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
- Inoue A, "Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations(NEJ002)", Ann Oncol, 24, pp.54~59 (2013)
- Sacher AG, "Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer", JAMA Oncol, 2, pp.1014~1022 (2016)
- Sorber L, "Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients", Lung Cancer, 107, pp.100~107 (2017)
- Papadimitrakopoulou VA, "Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial : osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non–small cell lung cancer", Cancer, 126, pp.373~380 (2020)
- Kim B, "Application of CRISPR", Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer, 2022, pp.22, 82~
- Kim Y, "Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy", Cancer Cell Int, 21, pp.50~ (2021)
- Shin Saeam, "Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing", Annals of Laboratory Medicine, 42(2), pp.141~149 (2022), 대한진단검사의학회[DOI]